Treatment with the synthetic CB1 and CB2 receptor agonist (WIN55, 212-2) and the synthetic selective CB2 agonist (AM-1241) delays the progression of ALS in animal models [215–221]. Here, CNR2 is linked to amyotrophic lateral sclerosis.